<DOC>
	<DOCNO>NCT00403767</DOCNO>
	<brief_summary>The purpose study compare efficacy safety rivaroxaban warfarin prevention blood clot brain ( referred stroke ) blood clot part body refer non-central nervous system systemic embolism ) patient non-valvular atrial fibrillation ( heart rhythm disorder ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Rivaroxaban With Warfarin Prevention Stroke Non-Central Nervous System Systemic Embolism Patients With Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description>Patients non-valvular atrial fibrillation risk stroke non-central nervous system ( non-CNS ) systemic embolism , randomize ( assigned chance ) receive treatment rivaroxaban warfarin , two different anticoagulant ( substance prevent blood clot ) . Treatment double-blinded ( neither patient study staff know study drug assign patient study ) . Patients assigned rivaroxaban receive rivaroxaban 20 mg orally ( p.o . ) daily ( OD ) plus warfarin placebo p.o . OD titrate target sham international normalize ratio ( INR ) 2.5 . Patients moderate renal impairment screen receive rivaroxaban 15 mg p.o . OD . Patients assign warfarin receive warfarin p.o . OD titrate target INR 2.5 plus rivaroxaban placebo p.o . OD . The maximum expected length treatment 32 month may extend 4 year .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients must document atrial fibrillation 2 separate occasion within 6 month screen History prior stroke , transient ischemic attack nonneurologic systemic embolism believe cardiac origin , least two follow risk factor : heart failure , hypertension , age 75 year great , diabetes mellitus Significant mitral stenosis Transient atrial fibrillation cause reversible disorder Active internal bleeding Severe disable stroke History intracranial bleeding Hemorrhagic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Embolism</keyword>
	<keyword>Non-central nervous system systemic embolism</keyword>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>Blood Clot</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Arrhythmias , Cardiac</keyword>
</DOC>